Evidence map›Paper›PMID 36969261›Full record

ArticleFrontiers in immunology2023

Humanized MISTRG as a preclinical

Paula Martinez-Sanz, Adrien R G Laurent, Edith Slot, Mark Hoogenboezem, Nikolina Bąbała, Robin van Bruggen, Anthony Rongvaux, Richard A Flavell, Godelieve A M Tytgat, Katka Franke and 4 more

Open access · goldFull text read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Paula Martinez-SanzSanquin Research and Landsteiner Laboratory, Department of Molecular Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Adrien R G LaurentSanquin Research and Landsteiner Laboratory, Department of Hematopoiesis, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Edith SlotSanquin Research and Landsteiner Laboratory, Department of Hematopoiesis, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Mark HoogenboezemSanquin Research and Landsteiner Laboratory, Department of Molecular Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Nikolina BąbałaSanquin Research and Landsteiner Laboratory, Department of Hematopoiesis, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Robin van BruggenSanquin Research and Landsteiner Laboratory, Department of Molecular Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Anthony RongvauxDepartment of Immunology, University of Washington, Seattle, WA, United States.
Richard A FlavellDepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, United States.
Godelieve A M TytgatPrincess Maxima Center for Pediatric Oncology, Department of Pediatric Oncology, Utrecht, Netherlands.
Katka FrankeSanquin Research and Landsteiner Laboratory, Department of Molecular Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Hanke L MatlungSanquin Research and Landsteiner Laboratory, Department of Molecular Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Taco W KuijpersSanquin Research and Landsteiner Laboratory, Department of Hematopoiesis, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Derk AmsenSanquin Research and Landsteiner Laboratory, Department of Hematopoiesis, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Julien J KarrichSanquin Research and Landsteiner Laboratory, Department of Hematopoiesis, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Amsterdam University Medical Centers · NLSanquin · NLFred Hutch Cancer Center · USHoward Hughes Medical Institute · USPrincess Máxima Center · NLUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: MISTRG mice have been genetically modified to allow development of a human myeloid compartment from engrafted human CD34+ haemopoietic stem cells, making them particularly suited to study the human innate immune system Methods and results: We could isolate human bone marrow neutrophils from humanized MISTRG mice and confirmed that all neutrophil maturation stages from promyelocytes (CD11b-CD16-) to end-stage segmented cells (CD11b+CD16+) were present. We documented that these cells possessed normal functional properties, including degranulation, reactive oxygen species production, adhesion, and antibody-dependent cellular cytotoxicity towards antibody-opsonized tumor cells Discussion: These results show that functional human neutrophils are generated and can be studied

Indexed as

Heterocyclic CompoundsNeutrophilsAnimalsBone MarrowHematopoietic Stem Cell MobilizationHumansImmunityMiceHeterocyclic Compoundsanimal modelhumanized immune system mouseMISTRGneutrophilsnext generation humanized mouse modelspreclinical study

Identifiers

PMID36969261
PMCPMC10032520
OpenAlexW4323567467

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read77
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.